IRIS MALIG: Open Payments
NPI 1932970662 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,902 in 71 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $2,017 · 2025 $1,902
Food & beverage: $1,902
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $737 |
| PFIZER INC. | 10 | $211 |
| Janssen Biotech, Inc. | 4 | $173 |
| Lundbeck LLC | 6 | $159 |
| Otsuka America Pharmaceutical, Inc. | 2 | $148 |
| Eisai Inc. | 1 | $122 |
| Novartis Pharmaceuticals Corporation | 4 | $98 |
| ARGENX US, INC. | 4 | $69 |
| UCB, Inc. | 2 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
Products named: QULIPTA, UBRELVY, NURTEC ODT, REXULTI, VYEPTI, Leqembi, KESIMPTA, VYVGART HYTRULO.
Industry payments across NV — which companies pay providers there.
